Dr. Flaherty on Resistance in BRAF-Mutant Melanoma

Video

Keith T. Flaherty, MD, director of Developmental Therapeutics at the Cancer Center of Massachusetts General Hospital, discusses resistance that develops in patients with BRAF-mutant melanoma.

Keith T. Flaherty, MD, director of Developmental Therapeutics at the Cancer Center of Massachusetts General Hospital, discusses resistance that develops in patients with BRAF-mutant melanoma.

Resistance to targeted therapies is inevitable, Flaherty explains, and is likely experienced in patients within 2 years. In a 2-year follow-up of the COMBI-d study, however, a large proportion of patients did not have disease progression and were doing well on therapy with the combination of dabrafenib (Tafinlar)/trametinib (Mekinist), he adds. Additionally, the 3-year data showed that there is a subgroup of patients with BRAF mutations with a less likely chance of resisting therapy.

These findings should lead to a new perception about drug resistance in the melanoma community, he explains.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,